Technology area: Biotechnology & Pharmaceuticals
29 pending office actions • 19 art units • 27 examiners • 0 of 29 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Vertex Pharmaceuticals Incorporated has 28 pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among 26 distinct examiners and 18 distinct art units, indicating that the portfolio is being examined across multiple technical and examination channels rather than concentrated in one unit.
SPENCE, JENNIFER SUZANNE is the busiest examiner, with 3 pending matters. The examiner distribution means most of the pending work is assigned outside that single examiner relationship. For prosecution planning, counsel should maintain a coordinated portfolio strategy while preserving matter-specific analysis across the separate art units and examiner assignments.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (3%) |
| §103 only | 5 (17%) |
| §102 only | 1 (3%) |
| §112 only | 1 (3%) |
| Double-patenting only | 5 (17%) |
| Double-patenting + other | 7 (24%) |
| Multi-statute (no §101) | 8 (28%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 3 | 66.9% | +46.0% |
| HOLLOMAN, NANNETTE | 1 | 60.7% | +23.1% |
| KRINOS, EMILY LYNN | 1 | — | — |
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18794848 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17669874 | PANCREATIC DIFFERENTIATION | BATES, KEENAN ALEXANDER | 37d overdue |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | ROGERS, ERIC JASON | 28d |
| 19100776 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | KRINOS, EMILY LYNN | — |
| 18929289 | CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof | SPENCE, JENNIFER SUZANNE | — |
| 18835221 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | REDWOOD, CHRISTOPHER EVAN | — |
| 18707756 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | GRABER, JAMES J | — |
| 18456269 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 | VIJAYARAGHAVAN, JAGAMYA NMN | — |
| 18270314 | ENHANCED DIFFERENTIATION OF BETA CELLS | MONTANARI, DAVID A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19046829 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | HOLLOMAN, NANNETTE | — |
| 18999125 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | PALENIK, JEFFREY T | — |
| 18972540 | DOSING REGIMENS FOR TREATING PAIN | SOROUSH, LAYLA | — |
| 18929289 | CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof | SPENCE, JENNIFER SUZANNE | — |
| 18904543 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | SPENCE, JENNIFER SUZANNE | — |
| 18904985 | Materials and Methods for Treatment of Hemoglobinopathies | SPENCE, JENNIFER SUZANNE | — |
| 18835242 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | CHONG, YONG SOO | — |
| 18791880 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1615 | 2 |
| 1631 | 2 |
| 1624 | 2 |
| 1632 | 2 |
| 1626 | 2 |
| 1691 | 2 |
| 1612 | 1 |
| 1622 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19046829 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | HOLLOMAN, NANNETTE | 1612 | §103 | Non-Final OA | — | Pending | Feb 06, 2025 |
| 19100776 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | KRINOS, EMILY LYNN | 1615 | §102§103§112 | Non-Final OA | — | Pending | Feb 03, 2025 |
| 18999125 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | PALENIK, JEFFREY T | 1615 | DP | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18972540 | DOSING REGIMENS FOR TREATING PAIN | SOROUSH, LAYLA | 1622 | §103 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18929289 | CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof | SPENCE, JENNIFER SUZANNE | — | §103§112Other | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18904543 | DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | SPENCE, JENNIFER SUZANNE | 1633 | §102§103DP | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18904985 | Materials and Methods for Treatment of Hemoglobinopathies | SPENCE, JENNIFER SUZANNE | 1633 | §102§103§112DP | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18794848 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | DAVIS, BRIAN J | 1614 | §112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18835242 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | CHONG, YONG SOO | — | Other | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18791880 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | O DELL, DAVID K | 1621 | §103DP | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18835221 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103§112DP | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18707756 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | GRABER, JAMES J | 1631 | §102§103 | Non-Final OA | — | Pending | May 06, 2024 |
| 18647137 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | DICKINSON, PAUL W | 1618 | §103 | Final Rejection | 26d overdue | Pending | Apr 26, 2024 |
| 18566176 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | RAO, PADMAJA S | 1627 | DP | Final Rejection | 52d overdue | Pending | Dec 01, 2023 |
| 18566279 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | BORALSKY, LUKE ALAN | 1624 | §112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18281154 | STEM CELL DIFFERENTIATION AND POLYMERS | CORDAS, EMILY ANN | 1632 | §103Other | Final Rejection | 71d | Pending | Sep 08, 2023 |
| 18456269 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18270314 | ENHANCED DIFFERENTIATION OF BETA CELLS | MONTANARI, DAVID A | 1632 | §102§103 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18036491 | METHODS OF MONITORING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY BY MEASURING POLYMERISED AAT | MARCSISIN, ELLEN JEAN | 1677 | §101§102§103§112Other | Final Rejection | — | Pending | May 11, 2023 |
| 18030519 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | KUCKLA, ANNA GRACE | 1626 | §102 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18030518 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103 | Final Rejection | 7d | Pending | Apr 06, 2023 |
| 18030520 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MARTIN, KEVIN STEPHEN | 1624 | §102§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | ROGERS, ERIC JASON | 1638 | §102§103§112 | Final Rejection | 28d | Pending | Jan 30, 2023 |
| 17820773 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS | HOWELL, THEODORE R | 1628 | §103DP | Non-Final OA | 25d overdue | Pending | Aug 18, 2022 |
| 17669874 | PANCREATIC DIFFERENTIATION | BATES, KEENAN ALEXANDER | 1631 | §102§103 | Non-Final OA | 37d overdue | Pending | Feb 11, 2022 |
| 17469665 | Compositions and Methods for Treatment of Duchenne Muscular Dystrophy | TATGE, LEXUS MARC | 1637 | §103DP | Non-Final OA | — | Pending | Sep 08, 2021 |
| 17345256 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | CHICKS, ASHLI ARIANA | 1626 | DP | Non-Final OA | 18d overdue | Pending | Jun 11, 2021 |
| 17293632 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | LEE, HOI YAN NMN | 1693 | DP | Final Rejection | — | Pending | May 13, 2021 |
| 17122543 | GCN2 INHIBITORS AND USES THEREOF | LEE, ANDREW P | 1691 | DP | Final Rejection | — | Pending | Dec 15, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVertex Pharmaceuticals Incorporated has 29 pending office actions as of October 2026, spread across 19 art units and 27 examiners.
Jennifer Suzanne Spence has the most, with 3 of Vertex Pharmaceuticals Incorporated's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
